The global Afatinib Dimaleate market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Afatinib dimaleate is an oral molecular targeted drug developed and produced by Boehringer Ingelheim, Germany. It is a TKIs with strong and irreversible dual inhibitory effect on EGFR and HER2, and was approved by THE US FDA in July 2013.It is not only suitable for first-line treatment of metastatic NSCLC with EGFR exon 19 deletion mutation or exon 21 (L858R) replacement mutation, but also a second - and third-line target drug for egFR-TKIS resistance.
Afatinib Dimaleate Market aims to provide a comprehensive presentation of the global market for Afatinib Dimaleate, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Afatinib Dimaleate. Afatinib Dimaleate Market contains market size and forecasts of Afatinib Dimaleate in global, including the following market information:
- Global Afatinib Dimaleate Market Revenue, 2018-2023, 2024-2032, ($ millions)
- Global top five companies in 2022 (%)
Clinical studies have shown that afatinib dimaleate reduces the risk of both cancer progression and death by 19% compared with first-generation EGFR TKI erlotinib, and significantly improves disease control rates, quality of life, and control of cancer symptoms.Prior to the Approval in China, afatinib has been approved in more than 70 countries for the treatment of PATIENTS with EGFR mutation-positive non-small cell lung cancer, and has become the preferred egFR-targeting drug in many countries.In addition, the drug was approved in 2016 by the US FDA and the European Union respectively for patients with advanced lung squamous cell carcinoma whose disease worsens during or after platinum-based chemotherapy.At present, the drug has been included in the medical insurance in China, and it can be expected that the market size of this product will gradually expand in the future.
We surveyed the Afatinib Dimaleate companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Afatinib Dimaleate Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Afatinib Dimaleate Market Segment Percentages, by Type, 2022 (%)
Global Afatinib Dimaleate Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Afatinib Dimaleate Market Segment Percentages, by Application, 2022 (%)
- Treatment of EGFR Mutated Non-Small Cell Lung Cancer
- Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
Global Afatinib Dimaleate Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Afatinib Dimaleate Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Afatinib Dimaleate revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Afatinib Dimaleate revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Boehringer Ingelheim Pharmaceuticals
- APExBIO Technology LLC
- Carbosynth Ltd
- Biorbyt
- Cayman Chemical Company
- Target Molecule Corp.
- Frontier Specialty Chemicals
- Combi-Blocks
- Selleck Chemicals
- AvaChem Scientific
- Advanced ChemBlocks Inc
- Glpbio
- Nanjing Xize Pharmaceutical Technology Co., Ltd
- Shandong Haiwo Biotechnology Co., Ltd
- J&K Scientific
- Shanghai McLin Biochemical Technology Co., Ltd
- Beijing Sjar Technology Development Co., Ltd.
- Beijing Wokai Biotechnology Co., Ltd
- Ningbo Zhenlei Chemical Co., Ltd.
- Beijing Mreda Technology Co., Ltd
- MedBio Pharmaceutical Technology Inc
- Shanghai Dibai Biotechnology Co., Ltd
Outline of Major Chapters:
Chapter 1: Introduces the definition of Afatinib Dimaleate, market overview.
Chapter 2: Global Afatinib Dimaleate market size in revenue.
Chapter 3: Detailed analysis of Afatinib Dimaleate company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Afatinib Dimaleate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
